9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

Key Takeaways Explain This Topic AI

The USPSTF gives a Grade B recommendation for a one-time screening for abdominal aortic aneurysm (AAA) using abdominal duplex ultrasonography in men aged 65 to 75 who have ever smoked (>=100 lifetime cigarettes); screening is selectively offered to men aged 65 to 75 who never smoked (Grade C), recommended against in women who never smoked (Grade D), and has insufficient evidence in women who ever smoked (Grade I).

Abdominal aortic aneurysm is defined as an infrarenal aortic diameter >=3.0 cm; surveillance ultrasound intervals are strictly size-dependent: 3.0 to 3.9 cm every 3 years, 4.0 to 4.9 cm every 12 months, and 5.0 to 5.4 cm every 6 months.

Indications for elective surgical AAA repair (EVAR or open surgical grafting) include maximal diameter >=5.5 cm in men, >=5.0 cm in women, rapid expansion (>0.5 cm in 6 months or >1.0 cm in 1 year), or any symptomatic aneurysm (abdominal, flank, or back pain, or distal atheroembolism) regardless of size.

The USPSTF assigns a Grade B recommendation for osteoporosis screening with central dual-energy X-ray absorptiometry (DEXA) in all women aged >=65 years, and in postmenopausal women younger than 65 whose calculated 10-year major osteoporotic fracture risk on FRAX is >=8.4% (the risk of an average 65-year-old white female without additional risk factors).

World Health Organization (WHO) DEXA diagnostic criteria define Normal as T-score >= -1.0, Osteopenia as T-score between -1.1 and -2.4, and Osteoporosis as T-score <= -2.5 at the femoral neck, total hip, or lumbar spine, or the occurrence of an adult fragility fracture of the hip or spine; pharmacotherapy is indicated for T-score <= -2.5, hip/vertebral fragility fracture, or osteopenia with FRAX 10-year hip fracture risk >=3.0% or major osteoporotic fracture risk >=20.0%.

Last updated: September 2026

Abdominal Aortic Aneurysm (AAA): Pathophysiology and Natural History

An Abdominal Aortic Aneurysm (AAA) is defined as a permanent, localized, full-thickness dilation of the abdominal aorta resulting in an outer-to-outer diameter >= 3.0 cm (or a segmental expansion exceeding 50% of the normal contiguous baseline aortic caliber). Over 90% of abdominal aortic aneurysms originate below the level of the renal arteries ( infrarenal aorta ) and frequently extend distally toward the aortic bifurcation and common iliac arteries. The normal diameter of the adult infrarenal aorta is approximately 1.5 to 2.0 cm in females and 1.7 to 2.3 cm in males; an aortic caliber between 2.5 and 2.9 cm is classified as ectatic.

The pathogenesis of AAA involves a chronic, transmural inflammatory cascade characterized by lymphocytic infiltration, oxidative stress, and the activation of matrix metalloproteinases (MMP-2 and MMP-9) . These proteolytic enzymes selectively degrade elastin and collagen within the aortic tunica media. Concurrently, depletion and apoptosis of vascular smooth muscle cells reduce matrix renewal, resulting in progressive thinning of the media, loss of structural tensile strength, and structural weakness. Governed by the Law of Laplace (T = P * r, where wall tension T equals distending blood pressure P multiplied by vessel radius r), as the aneurysmal radius increases, the tensile wall stress escalating on the aortic wall intensifies exponentially, predisposing the aneurysm to accelerated expansion and catastrophic transmural rupture.

Epidemiological Risk Factors for AAA Development and Expansion

Abdominal aortic aneurysms are characteristically silent until catastrophic acute rupture occurs, which carries an overall mortality rate exceeding 80% to 90% (with over 50% dying before reaching the hospital). Identifying risk factors is essential to guide population-level ultrasound screening:

Cigarette Smoking : The single most powerful, modifiable environmental risk factor. A history of smoking (defined in screening guidelines as having smoked >= 100 lifetime cigarettes ) increases the relative risk of developing an AAA by 3- to 5-fold in a dose-dependent fashion (quantified by pack-years). Smoking also significantly accelerates the rate of aneurysmal expansion and quadruples the risk of rupture.

Male Sex : AAA is 4 to 6 times more prevalent in males than in females. However, when aneurysms do occur in females, they expand more rapidly and rupture at significantly smaller diameters.

Advanced Age : Prevalence escalates sharply after age 65.

Family History in a First-Degree Relative : Confers an odds ratio of approximately 4.0; familial aneurysms exhibit earlier presentation, faster growth, and higher rupture risk.

Atherosclerotic Cardiovascular Disease & Hypertension : Strongly associated with AAA presence.

Protective Factors / Paradoxical Associations : Black race, Hispanic ethnicity, female sex, and, paradoxically, diabetes mellitus are associated with a significantly lower prevalence of AAA and slower aneurysmal growth rates (hypothesized to result from advanced glycation end-product cross-linking of medial collagen fibers).

USPSTF AAA Screening Recommendations: The Demographic Grade Matrix

The USPSTF established demographic screening criteria based on extensive meta-analyses demonstrating that one-time screening in older men with a smoking history significantly reduces AAA-related mortality and rupture rates without causing significant procedural harms:

USPSTF AAA Screening Recommendations by Sex and Smoking History

Demographic Cohort Smoking History Definition USPSTF Grade Clinical Recommendation & Action

Men aged 65 to 75 years Ever-Smoker (>= 100 lifetime cigarettes) Grade B Offer one-time screening with abdominal duplex ultrasonography routinely

Men aged 65 to 75 years Never-Smoker (<100 lifetime cigarettes) Grade C Selectively offer screening based on shared decision-making, family history of AAA, personal history of CVD, and patient preferences

Women aged 65 to 75 years Ever-Smoker (>= 100 lifetime cigarettes) Grade I Insufficient evidence ; balance of benefits and harms cannot be determined (SVS recommends screening if family history or smoking is present)

Women aged 65 to 75 years Never-Smoker (<100 lifetime cigarettes) Grade D Recommend AGAINST screening ; prevalence is exceptionally low (<0.5%) and harms of incidental discovery/surgery exceed benefit

Adults aged > 75 years Ever- or Never-Smoker N/A Screening is not recommended unless the patient possesses exceptional physiological fitness, is an elective surgical candidate, and has never been screened

Exam Pearl : On the ABFM examination, note the exact cigarette threshold. A 67-year-old man who smoked 1 pack of cigarettes a day for 2 years in college (totaling >700 cigarettes) qualifies as an "ever-smoker" (>= 100 cigarettes) and mandates screening, even if he has not touched tobacco for 45 years.

Diagnostic Ultrasonography, Surveillance Cadence, and Thresholds for Intervention

Abdominal duplex ultrasonography is the gold standard diagnostic and screening modality. It boasts a sensitivity of 95% to 100% and specificity approaching 100%, is completely non-invasive, incurs no ionizing radiation or nephrotoxic iodinated contrast, and is highly cost-effective. CT angiography is reserved exclusively for pre-operative anatomic planning or acute evaluation of suspected symptomatic rupture.

Once an infrarenal aorta is measured >= 3.0 cm, the patient enters a standardized, diameter-calibrated surveillance program:

Abdominal Aortic Diameter Classification, Surveillance Intervals, and Rupture Risks

• Aortic Dimension Clinical Classification Annual Rupture Risk Recommended Surveillance Modality & Cadence
• < 3.0 cm Normal Aortic Caliber < 0.1% No further surveillance required; negative screen is durable for life
• 3.0–3.9 cm Small Aortic Aneurysm < 0.5% Repeat abdominal ultrasonography every 3 years
• 4.0–4.9 cm Medium Aortic Aneurysm 1.0%–1.5% Repeat abdominal ultrasonography every 12 months (annually)

5.0–5.4 cm Large Aortic Aneurysm 3.0%–5.0% Repeat abdominal ultrasonography every 6 months ; vascular surgery consultation

>= 5.5 cm (Men) ; >= 5.0 cm (Women) Surgical Intervention Threshold >= 10%–20% Elective surgical repair (EVAR vs. open repair); urgent referral

Indications for Elective Surgical Intervention (EVAR vs. Open Repair)

The primary objective of AAA screening and surveillance is to identify aneurysms that reach criteria for elective repair before catastrophic rupture occurs:

Absolute Diameter Threshold :

Men : Maximal aortic diameter >= 5.5 cm .

Women : Maximal aortic diameter >= 5.0 cm (women exhibit smaller baseline aortic calibers and a 4-fold higher rupture rate at equivalent diameters between 5.0 and 5.4 cm).

Rapid Expansion Rate :

Documented growth > 0.5 cm within a 6-month window , OR

Documented growth > 1.0 cm within a 12-month window .

Symptomatic Aneurysm :

Any patient presenting with new abdominal pain, back pain, flank tenderness, a tender pulsatile abdominal mass, or distal microembolization ("blue toe syndrome" or "trash foot") attributable to an aneurysm of any size warrants emergent vascular surgical evaluation, as symptoms herald impending or contained rupture.

Surgical Modalities: EVAR vs. Open Surgical Grafting

Endovascular Aneurysm Repair (EVAR) : A minimally invasive procedure where an expandable stent-graft is deployed via transfemoral access under fluoroscopic guidance to exclude the aneurysmal sac. EVAR has significantly lower 30-day perioperative morbidity and mortality (1% to 2% vs. 4% to 5% for open repair) and faster hospital discharge. However, EVAR requires lifelong imaging surveillance (contrast CT or ultrasound) to monitor for endoleaks (persistent perfusion of the aneurysmal sac), graft migration, and structural fatigue.

Open Surgical Repair : Involves a midline laparotomy, retroperitoneal dissection, aortic cross-clamping, and sewing a synthetic Dacron or PTFE tube graft. Open repair carries higher immediate perioperative cardiopulmonary and renal risks, but exhibits superior long-term structural durability and rarely requires re-intervention.

Medical Management and Cardiovascular Risk Optimization in AAA

Because the vast majority of AAA patients suffer from generalized atherosclerosis, medical optimization is mandatory:

Smoking Cessation : The single most effective conservative intervention. Quitting smoking reduces the aneurysmal growth rate by 20% to 30% and significantly diminishes rupture risk.

Blood Pressure Optimization : Control blood pressure to <130/<80 mm Hg to reduce mechanical wall stress.

Moderate- to High-Intensity Statin Therapy : Prescribed for all patients with AAA to stabilize plaque and reduce composite cardiovascular mortality.

Antiplatelet Therapy : Low-dose aspirin (81 mg/day) is indicated for secondary cardiovascular prevention.

High-Yield Board Fact : Randomized controlled trials have demonstrated that beta-blockers do NOT reduce the rate of AAA expansion or rupture . While beta-blockers are essential for thoracic aortic aneurysms and aortic dissection, they have no proven therapeutic benefit in halting infrarenal abdominal aortic dilation. They should be prescribed only if standard independent cardiac indications (e.g., prior MI, angina, heart failure) exist.

Osteoporosis: Pathophysiology and Clinical Burden of Fragility Fractures

Osteoporosis is a systemic skeletal disorder characterized by low bone mineral density (BMD), microarchitectural deterioration of bone tissue, and compromised bone strength, leading to an increased susceptibility to fragility fractures . A fragility fracture is clinically defined as a low-trauma fracture resulting from mechanical forces equivalent to or less than a fall from a standing height (or occurring in the absence of recognizable trauma, such as sneezing, coughing, or reaching).

Bone remodeling is governed by a delicate homeostatic balance between osteoclasts (hematopoietic origin; resorb mineralized bone via acid and cathepsin K secretion) and osteoblasts (mesenchymal origin; synthesize osteoid collagen matrix and mineralize bone). Remodeling is orchestrated through the RANK / RANKL / Osteoprotegerin (OPG) cytokine pathway. In postmenopausal women, the cessation of ovarian estrogen synthesis unleashes a surge in pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) that upregulate RANKL expression on osteoblasts and stromal cells. RANKL binds its cognate receptor RANK on osteoclast precursors, dramatically accelerating osteoclastogenesis, osteoclast survival, and bone resorption. Resorption outpaces osteoblastic bone formation, leading to preferential thinning and perforating loss of trabecular microarchitecture (cancellous bone in vertebrae and femoral neck) and cortical porosity.

Clinical Consequences of Fragility Fractures

Hip Fractures : Associated with devastating morbidity; 1-year all-cause mortality following an osteoporotic hip fracture ranges between 20% and 30% , and fewer than 50% of surviving patients ever regain their pre-fracture functional independence.

Vertebral Compression Fractures : The most common osteoporotic fracture. Up to two-thirds are clinically silent, presenting insidiously as progressive height loss (>1.5 inches [4 cm] historically or >0.8 inches [2 cm] prospectively), thoracic hyperkyphosis ("dowager's hump"), restrictive pulmonary dysfunction, early satiety, and chronic back pain.

Distal Radius (Colles') Fractures : Classic early postmenopausal fragility fracture resulting from a fall onto an outstretched hand.

Screening Guidelines: USPSTF Grade B Recommendations and Clinical Risk Triggers

The USPSTF establishes definitive guidelines for bone mineral density screening:

1. Universal Screening in Older Women

Recommendation : Routine screening for osteoporosis with central dual-energy X-ray absorptiometry (DEXA) is recommended for all women aged >= 65 years ( USPSTF Grade B ).

Evidence : High certainty of moderate net clinical benefit in reducing osteoporotic fractures and associated mortality.

2. Risk-Based Screening in Postmenopausal Women Younger Than 65 Years

Recommendation : Screening with central DEXA is recommended for postmenopausal women younger than 65 years whose calculated fracture risk equals or exceeds that of an average 65-year-old white female without additional risk factors ( USPSTF Grade B ).

Quantitative Threshold : On the World Health Organization FRAX tool , an average 65-year-old white woman with zero clinical risk factors carries a 10-year probability of major osteoporotic fracture (MOF) of 8.4% . Therefore, any postmenopausal woman younger than 65 whose FRAX 10-year MOF risk is >= 8.4% warrants central DEXA screening.

Primary Care Clinical Risk Factors Prompting Early Screening :

Low body weight : Body weight < 127 lbs (57.6 kg) or BMI < 21 kg/m2.

Personal history of prior adult low-trauma fragility fracture .

Parental history of hip fracture (especially maternal hip fracture).

Current cigarette smoking (accelerates hepatic estrogen metabolism and inhibits osteoblast function).

Excessive alcohol intake (>= 3 drinks/day).

Rheumatoid arthritis .

Chronic systemic glucocorticoid therapy : Prednisone equivalent >= 5 mg/day for >= 3 consecutive months.

Secondary causes : Untreated hyperthyroidism, primary hyperparathyroidism, hypogonadism, malabsorption (celiac disease, Crohn's, gastric bypass), chronic liver disease, premature surgical or natural menopause before age 40 or 45.

3. Screening in Men

USPSTF Position : The USPSTF concludes that current clinical evidence is insufficient to evaluate the balance of benefits and harms of routine screening for osteoporosis in men ( Grade I statement ).

Specialty Society Consensus (BHOF / Endocrine Society) : The Bone Health & Osteoporosis Foundation (BHOF) recommends screening all men aged >= 70 years , and men aged 50 to 69 years with clinical risk factors (e.g., prolonged glucocorticoids, androgen deprivation therapy for prostate cancer, hypogonadism, or prior adult fragility fracture).

Dual-Energy X-Ray Absorptiometry (DEXA): Physics, T-Scores vs. Z-Scores

Central Dual-Energy X-ray Absorptiometry (DEXA) represents the undisputed clinical gold standard for measuring bone mineral density (expressed as areal density in g/cm2). The physical scanner passes two low-dose X-ray beams with distinct photoelectric energy peaks through skeletal tissues. Soft tissues attenuate both energy beams equally, while mineralized hydroxyapatite attenuates high-energy photons selectively, enabling precise computer subtraction of soft tissue and accurate quantification of bone mass with minimal radiation exposure (<1/10 the dose of a standard chest radiograph).

Skeletal Measurement Sites

Guidelines mandate measuring BMD at three central sites :

• Femoral Neck
• Total Hip
• Lumbar Spine (L1–L4)

Diagnostic Rule : The patient's definitive diagnostic category is determined by the lowest T-score among the femoral neck, total hip, and lumbar spine.

• T-Score vs. Z-Score: The Critical Board Distinction
• T-Score = (Patient BMD - Young Adult Reference Mean BMD) / Young Adult Standard Deviation
• Z-Score = (Patient BMD - Age/Sex/Ethnicity-Matched Reference Mean BMD) / Matched Standard Deviation

T-Score :

Compares the patient's BMD to the mean peak bone mass of a healthy, young adult sex-matched reference population (aged 20 to 29 years).

Applicable Cohort : Postmenopausal women and men aged >= 50 years.

Used exclusively to establish World Health Organization diagnostic categories.

Z-Score :

Compares the patient's BMD to an age-, sex-, and race/ethnicity-matched population.

Applicable Cohort : Premenopausal women, men younger than 50 years, and children.

A Z-score <= -2.0 is defined as "below the expected range for age" and strongly signals secondary osteoporosis (e.g., hyperparathyroidism, Cushing syndrome, multiple myeloma, hypogonadism, celiac disease, or systemic mastocytosis), mandating a comprehensive secondary diagnostic workup.

WHO Diagnostic Categories for Bone Mineral Density

Diagnostic Category T-Score Criteria (Femoral Neck, Total Hip, or Lumbar Spine) Clinical Interpretation & Fracture Risk

Normal Bone Mineral Density T-Score >= -1.0 SD Normal fracture risk relative to healthy young adults

Osteopenia (Low Bone Mass) -2.4 SD <= T-Score <= -1.1 SD Moderate fracture risk; warrants fracture risk calculation via FRAX

Osteoporosis T-Score <= -2.5 SD High fracture risk; clinical criteria met for pharmacotherapy

Severe (Established) Osteoporosis T-Score <= -2.5 SD PLUS a documented fragility fracture Extreme fracture risk; candidate for first-line anabolic bone therapy

Crucial Clinical Rule : Regardless of the measured DEXA T-score, the occurrence of a low-trauma fragility fracture of the hip or spine establishes the clinical diagnosis of Osteoporosis without requiring bone density confirmation.

The FRAX Assessment Tool and Indications for Pharmacotherapy

The Fracture Risk Assessment Tool (FRAX) is a computer-driven algorithm developed by the World Health Organization that integrates femoral neck BMD with clinical risk factors to calculate a patient's individualized 10-year probability of sustained fracture:

10-Year Probability of Hip Fracture

10-Year Probability of a Major Osteoporotic Fracture (MOF) : Composite of hip, clinical spine, distal forearm (wrist), or proximal humerus fracture.

• FRAX Input Variables
• Age (40 to 90 years)
• Sex
• Weight and Height (BMI)
• Previous adult fragility fracture
• Parental history of fractured hip
• Current tobacco smoking
• Systemic glucocorticoid therapy (>= 5 mg/day prednisone for >= 3 months)
• Rheumatoid arthritis (confirmed diagnosis)
• Secondary osteoporosis causes
• Alcohol intake >= 3 units/day
• Femoral neck bone mineral density (optional but enhances precision)
• Guideline Criteria for Initiating Pharmacologic Therapy

According to the Bone Health & Osteoporosis Foundation (BHOF) and Endocrine Society guidelines, prescription pharmacotherapy (e.g., oral bisphosphonates such as alendronate or risedronate) is indicated for postmenopausal women and men aged >= 50 years who fulfill any one of the following three criteria :

Documented hip or vertebral fragility fracture (clinical or asymptomatic vertebral fracture identified on lateral spine imaging).

DEXA T-score <= -2.5 at the femoral neck, total hip, or lumbar spine (after ruling out secondary causes).

Osteopenia (T-score between -1.1 and -2.4) AND elevated FRAX thresholds :

Calculated 10-year probability of Hip Fracture >= 3.0% , OR

Calculated 10-year probability of Major Osteoporotic Fracture (MOF) >= 20.0% .

Monitoring Response to Pharmacotherapy and Surveillance Intervals in Osteopenia

Patients Receiving Pharmacotherapy : Repeat central DEXA every 1 to 2 years after initiating or changing pharmacologic therapy to evaluate therapeutic response and bone stability.

Untreated Patients with Low Bone Mass (Osteopenia) :

Mild Osteopenia (T-score -1.01 to -1.49): Repeat DEXA in 10 to 15 years .

Moderate Osteopenia (T-score -1.50 to -1.99): Repeat DEXA in 3 to 5 years .

Advanced Osteopenia (T-score -2.00 to -2.49): Repeat DEXA in 1 to 2 years .

Board Exam Traps & High-Yield Clinical Pearls

Exam Trap — Peripheral Bone Density Testing : Peripheral DEXA (pDEXA of the finger, forearm, or heel) and quantitative heel ultrasound (QUS) are commercial screening tools. They estimate fracture risk but CANNOT be used to diagnose osteoporosis, cannot establish official T-scores, and cannot be used to monitor therapeutic response . Any abnormal peripheral screening test mandates follow-up with central DEXA (hip and spine) to confirm the diagnosis and guide pharmacotherapy.

Exam Pearl — Structural Artifacts in Lumbar Spine DEXA : Severe spinal osteoarthritis, degenerative disc disease, osteophytes, facet joint arthropathy, aortic vascular calcifications, and prior compression fractures falsely elevate measured lumbar spine BMD (producing artificially "normal" or falsely elevated spine T-scores). In elderly patients with significant spinal degenerative changes, the femoral neck and total hip T-scores are far more accurate and must be utilized to establish the diagnosis.

Exam Pearl — Mandatory Pre-Treatment Laboratory Workup : Prior to prescribing bisphosphonate therapy, clinicians must obtain: 1) Serum Calcium and 25-hydroxyvitamin D (hypocalcemia and severe vitamin D deficiency must be corrected prior to initiating bisphosphonates or denosumab to prevent life-threatening hypocalcemia); 2) Serum Creatinine / eGFR (oral bisphosphonates are contraindicated if eGFR < 35 mL/min/1.73m2; zoledronic acid is contraindicated if eGFR < 35 mL/min/1.73m2; denosumab may be used in renal failure but carries a high risk of hypocalcemia).

Loading diagram... AAA Screening & Surveillance and Osteoporosis Screening & Treatment Pathway